Jiuyu Liu , Pradeep B. Lukka , Victoria A. Ektnitphong , Keyur R. Parmar , Santosh Wagh , Yan Lu , Robin B. Lee , Dimitri Scherbakov , Han Wang , Matthew D Zimmerman , Bernd Meibohm , Gregory T. Robertson , Vêronique Dartois , Erik C. Böttger , Anne J. Lenaerts , Richard E. Lee
{"title":"Enhancing the therapeutic window for Spectinamide anti-tuberculosis Agents: Synthesis, Evaluation, and activation of phosphate prodrug 3408","authors":"Jiuyu Liu , Pradeep B. Lukka , Victoria A. Ektnitphong , Keyur R. Parmar , Santosh Wagh , Yan Lu , Robin B. Lee , Dimitri Scherbakov , Han Wang , Matthew D Zimmerman , Bernd Meibohm , Gregory T. Robertson , Vêronique Dartois , Erik C. Böttger , Anne J. Lenaerts , Richard E. Lee","doi":"10.1016/j.bmcl.2024.129934","DOIUrl":null,"url":null,"abstract":"<div><p>Spectinamides are a novel class of narrow-spectrum antitubercular agents with the potential to treat drug-resistant tuberculosis infections. Spectinamide <strong>1810</strong> has shown a good safety record following subcutaneous injection in mice or infusion in rats but exhibits transient acute toxicity following bolus administration in either species. To improve the therapeutic index of <strong>1810</strong>, an injectable prodrug strategy was explored. The injectable phosphate prodrug <strong>3408</strong> has a superior maximum tolerated dose compared to <strong>1810</strong> or Gentamicin. Following intravenous administration in rodents, prodrug <strong>3408</strong> was quickly converted to <strong>1810</strong>. The resulting <strong>1810</strong> exposure and pharmacokinetic profile after <strong>3408</strong> administration was identical to equivalent molar amounts of <strong>1810</strong> given directly by intravenous administration. <strong>3408</strong> and the parent <strong>1810</strong> exhibited similar overall efficacy in a BALB/c acute tuberculosis efficacy model. Delivery of <strong>1810</strong> in phosphate prodrug form, therefore, holds the potential to improve further the therapeutic index of an already promising tuberculosis antibiotic.</p></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"112 ","pages":"Article 129934"},"PeriodicalIF":2.5000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960894X24003366/pdfft?md5=f502c19cc97d16b2cebd89ff9b00618b&pid=1-s2.0-S0960894X24003366-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic & Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960894X24003366","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Spectinamides are a novel class of narrow-spectrum antitubercular agents with the potential to treat drug-resistant tuberculosis infections. Spectinamide 1810 has shown a good safety record following subcutaneous injection in mice or infusion in rats but exhibits transient acute toxicity following bolus administration in either species. To improve the therapeutic index of 1810, an injectable prodrug strategy was explored. The injectable phosphate prodrug 3408 has a superior maximum tolerated dose compared to 1810 or Gentamicin. Following intravenous administration in rodents, prodrug 3408 was quickly converted to 1810. The resulting 1810 exposure and pharmacokinetic profile after 3408 administration was identical to equivalent molar amounts of 1810 given directly by intravenous administration. 3408 and the parent 1810 exhibited similar overall efficacy in a BALB/c acute tuberculosis efficacy model. Delivery of 1810 in phosphate prodrug form, therefore, holds the potential to improve further the therapeutic index of an already promising tuberculosis antibiotic.
期刊介绍:
Bioorganic & Medicinal Chemistry Letters presents preliminary experimental or theoretical research results of outstanding significance and timeliness on all aspects of science at the interface of chemistry and biology and on major advances in drug design and development. The journal publishes articles in the form of communications reporting experimental or theoretical results of special interest, and strives to provide maximum dissemination to a large, international audience.